Peptide Documentation Checklist: FDA Vote Prep Guide

What the July 2026 Vote Did and Did Not Change

On July 23-24, 2026, the Pharmacy Compounding Advisory Committee reviewed seven unapproved peptides and recommended six of them for the 503A bulks list (McDermott Will & Emery, 2026-07-28). BPC-157, KPV, and TB-500 each cleared 8-6 with one abstention; MOTs-c passed 7-5; Semax passed 8-5; Epitalon passed 7-4; Emideltide (DSIP) failed 6-7. RAPS recorded the Epitalon tally as 7-5, so treat that single figure as unsettled.

⚠️ Warning: The recommendation is advisory only. As Mintz notes, an advisory vote is not an agency action, and any listing still requires notice-and-comment rulemaking. Nothing has legally changed yet, and appearing on the list is a compounding-status question, not a safety finding.

What already applies is unchanged: under section 503A, a bulk drug substance needs a valid certificate of analysis and must come from an establishment registered with FDA under section 510 (FDA, 2026-05-14). FDA also describes the 503A list as updated on an ongoing basis under an interim policy with three categories. That is why the peptide documentation checklist below focuses on records you control today.

How to Use This Peptide Documentation Checklist

This checklist covers six areas: identity, hreinleika, analytical methods, impurity profiles, sourcing, and intended use. They map onto four phases of work: pre-synthesis, in-process, release, and hand-over. Each item is phrased as a binary judgment, so you can answer yes or no and move on.

Two scope limits apply. This is documentation guidance, not legal or regulatory advice; consult qualified regulatory counsel before making compliance decisions. And list status and safety status are separate questions: appearing on or off a list does not by itself establish whether a peptide is safe.

Work through the phases in order, then use the consolidated table at the end to confirm nothing was missed. The sections that follow define what counts as adequate custom peptide synthesis documentation for each item.

Phase 1 — Pre-Synthesis and Sourcing Records

The records that are cheapest to create are the hardest to reconstruct later. A lot number written on a receiving log at intake takes seconds; recovering that same lot number eighteen months later, when a partner asks which building blocks went into a batch, can take days and may end in an answer nobody can defend.

Four items belong in this phase, and each is a binary check:

• Amino acid building block and resin lot numbers are recorded, with the supplier’s CoA on file for each. Traceability has to survive at the lot level, not the catalog level. A supplier qualification packet should carry a batch-specific CoA that records the tests, specifications and results for that lot, plus lot and SKU traceability back to a documented synthesis route (lyochem lab notes, 2026-06-01). The FDA’s own outline of section 503A requirements points the same direction, expecting a valid CoA and 510-registered manufacture (FDA, 2026-05-14).

• Reference standard identity, lot number and expiry are documented.

• A written intended-use statement distinguishes research use from compounding.

• Chain of custody from receipt to storage is documented.

The reference standard’s expiry date is the item teams most often file in the wrong place. It belongs in the batch record, not in a lab notebook, because the batch record is what a reviewer or partner actually reads. If the standard expired before the run, the identity data generated against it carries a qualification the record should state on its face, and a notebook entry three shelves away will not surface that.

Phase 2 — Identity Documentation

Identity is a separate question from purity, and a 98% purity figure does not answer it. Purity testing confirms how much of the material elutes as the main peak; it does not confirm that the main peak is the peptide you ordered. As Peptra Labs explains in its certificate of analysis guide, purity testing is not identity confirmation “unless an identity assay exists for that batch” (2026-05-22). That conditional wording is the whole point: identity has to be demonstrated by a method that can distinguish your sequence from a near neighbour.

Three methods carry that specificity. Mass spectrometry establishes molecular mass, with electrospray ionization tolerances of ±1 Da below 5,000 Da and ±2 Da above it, and MALDI-TOF holding ±0.5 Da on shorter peptides (Lyos Labs, 2026-04-08). Amino-acid analysis reports composition after hydrolysis, and peptide mapping locates the sequence itself. Each produces its own record: the spectrum or composition report, the expected versus observed value, the instrument and acquisition parameters, and the analyst and date.

On validation scope, the reading of ICH Q2(R2) that Peptide Staff applies to peptide methods is that identity methods do not need full validation across every characteristic, but they do need to show specificity (2026-09-11). Read that as a documentation instruction rather than a relaxation: the file still has to prove the method discriminates, which means a specificity rationale, a representative spectrum, and a stated acceptance window. This is where peptide analytical method validation expectations differ most sharply between identity and assay work, and where a thin file is easiest to spot.

Phase 3 — Purity Documentation and What the Number Means

A CoA purity figure is an area-percent measure, and it systematically reads high. The record has to state what was measured and how, or the number invites a false conclusion about content.

The distinction is not academic. In one cited metrology example, a manufacturer-stated content of 983.72 mg/g sat against a mass-balance determination of 896.36 ± 0.68 mg/g, a gap on the order of seventy-plus milligrams per gram (lineara, 2026-05-01). Treat that as a single-upstream illustration, not a general rule.

Water and counter-ions explain much of the difference. Lyophilized peptides are hygroscopic, and failing to correct for water can bias results by several percent; Karl Fischer reports water as % w/w and feeds the net-content and salt-correction calculation (clarascience, 2026-07-15). Counter-ions such as trifluoroacetate, acetate and chloride contribute to batch mass but are not detected at 214 nm (peptidetrace, 2026-05-23).

So the record must state the reporting convention: as-is, anhydrous, or salt-free. The 95%, 98% og 99%+ bands are marketing conventions rather than validated specifications; a 95% specification may contain up to 5% by weight of related substances, synthesis byproducts, residual protecting groups or counter-ions (peptidetrace, 2026-05-23).

Key Takeaway: An area-percent figure answers “how much of the UV-absorbing material is the main peak”, not “how much peptide is in the vial”.

Phase 4 — Analytical Method Records

A method is only reconstructable if the file names the column, the mobile phase, the gradient, the detection wavelength and the integration rules. Everything else is a summary that a receiving lab has to rebuild from scratch.

Conventional peptide practice records a defined parameter set. Column chemistry defaults to C18 for short and mid-length peptides, with C8 for over-retained hydrophobic sequences and 300 Å for longer chains. Dimensions are typically 4.6 × 150 mm for UV purity work and 2.1 × 100 mm for LC-MS, with pore sizes of 100-130 Å and particle sizes of 3.5 or 2.7 µm, dropping to 1.7-1.8 µm for LC-MS (reversed-phase HPLC method parameters for peptides, 2026-09-15). Mobile phases run 0.1% TFA (roughly 13 mM) in water and acetonitrile, switching to 0.1% formic acid for LC-MS. Gradients are scouting at 5-65% B over 60 minutes at 1.0 ml/mín, or focused at 0.25-0.5% B/min, with a 90-95% B wash of at least 5 minutes and re-equilibration of about 10 column volumes. The measured dwell volume belongs in the method, and detection sits at 214 nm for the peptide bond.

Method status is a separate record from method content. A validated method has been formally demonstrated fit for its intended purpose across the relevant performance characteristics, while a qualified method is a limited demonstration of fitness for a narrower, defined purpose without the full validation evidence (peptide analytical method validation guidelines, 2026-09-11). Which characteristics apply depends on method purpose. Under the adopted ICH Q2(R2) guideline, effective 14 June 2024, the named characteristics include accuracy, precision, specificity, detection limit, quantitation limit, linearity and range. In peptide practice, assay methods carry the full set, with a range of 80-120% of target, recovery of 98-102%, RSD at or below 2% and r² of at least 0.999. Impurity methods lean on specificity and sensitivity instead: a range from the reporting threshold to 120% of the specification limit, a limit of detection well below the reporting threshold, a limit of quantitation at or below it, and forced degradation to establish specificity. Treat those figures as peptide convention rather than as ICH requirements.

System suitability criteria and integration settings are records in their own right, not settings buried in the software. Write down the resolution, tailing factor, retention time repeatability and signal-to-noise thresholds that a run must meet before its result counts, and record Tilbúið peptíð the integration rules (baseline mode, smoothing, minimum area threshold, manual intervention and who authorised it). A purity figure produced under unstated integration rules cannot be defended, and a method that cannot be reconstructed cannot be transferred to a larger scale.

Phase 5 — Impurity Profile Documentation

A defensible impurity record lists the classes you looked for and the method that would have found each one. Deletion sequences show as a mass deficit for the absent residue; truncated chains sit at lower mass; oxidised methionine appears as a +16 Da satellite; deamidated Asn or Gln shifts by +1 Da with altered retention; racemisation changes activity without changing mass; TFA adducts show up directly in the chromatogram (lyoslabs, 2026-04-08). Because these species can be close in both mass and retention, a single chromatogram will not separate them all, which is why peptide purity and impurity profile documentation pairs orthogonal methods rather than one run.

Thresholds for reporting, identification and qualification trace to ICH Q3B(R2), which sets identification typically at 0.10% or 1.0 mg per day intake, whichever is lower. That framework does not apply to research-grade material in the same formal sense, so state which threshold basis your record uses.

Phase 6 — Release and Hand-Over Records

Assemble the hand-over as a package, not as a folder of files. The package is the artifact a partner actually reads, and a missing element blocks a program even when the underlying work was sound. Start with the peptide certificate of analysis requirements: the product name must match the vial label, the batch or lot must match both the vial and the order paperwork, and the report must carry the test date, the analytical method, the batch-specific purity result, the testing laboratory, and a lab-controlled public report URL rather than a supplier-hosted page alone (Peptra Labs, 2026-05-22). Peptíð Framleiðsla

Bind every reported value to the raw data behind it, and keep the version and approval trail with the record set. Records should be attributable, legible, contemporaneous, original and accurate, and the set should let a reviewer reconstruct the batch without contacting the lab.

Fyrir ábending: If a reviewer has to email you to understand a number, the package is incomplete. Um

Documentation packages of this kind are the workflow MOL breytingar supports.

Consolidated Peptide Documentation Checklist

This peptide documentation checklist condenses the six coverage areas into one printable page. Each row is a binary judgment: either the record exists in the lot file or it does not. Hand it to the team before the next campaign starts, and treat any “no” as an open item rather than a formality.

Two habits keep this page useful. First, review it at the point each record is generated, not at release, because reconstructing an integration rule or a system suitability result months later is where most gaps appear. Second, keep the raw data behind every row, since a summary table without the underlying chromatogram or spectrum does not survive scrutiny.

Key Takeaway: A documentation package is only as strong as its weakest row. If any item above cannot be answered with a specific record, that is the item to fix before the next lot is released.

Common Questions About Peptide Documentation

How long should peptide documentation be retained?

Retain records for as long as the material can be in use or referenced, then add a defined margin on top of that. Because a lot may be held, re-tested, or shipped years after release, the retention period should be set by the longest plausible use window, not by the release date. Where a lot is tied to a sterility or endotoxin claim, the retention clock follows the longest applicable requirement, since those records are the ones most likely to be requested later.

What if a supplier’s certificate of analysis omits a method detail?

Ask the supplier for the missing detail in writing before you accept the lot, and record the request and the response. A certificate that reports a purity figure without naming the method, column, or detection wavelength cannot be independently interpreted, so the gap is a documentation defect rather than a formatting preference. If the supplier will not supply it, treat the lot as unverified for that attribute and say so in your own records.

Is a qualified method acceptable for a given purpose?

Yes, provided the qualification is documented against the intended use and the limits are stated. A qualified method is acceptable when its fitness for the specific purpose has been demonstrated and recorded; it is not acceptable as a substitute for a validated method where the purpose requires validated performance. The deciding question is what the result will be used to support, not how the method was labeled.

What should we do when a lot fails system suitability?

Do not release the lot, and do not re-integrate or re-run until the failure is investigated and the cause is identified. A system suitability failure is a signal about the method or the instrument as much as about the sample, so the investigation should establish which before any repeat injection is treated as a valid result. Document the failure, the investigation, and the resolution together, because the failed run is part of the lot’s record.

Key Takeaway: Each answer above stands alone, so you can lift the one you need into a supplier query, an SOP note, or a review meeting without losing its context.

Next Steps

The regulatory outcome is not yours to control; the record set is. Start tomorrow with the phase that is weakest in your current files, usually Phase 4, and work forward. A peptide documentation checklist only helps if someone can hand the file to a reviewer who was not in the room.

If you would like a worked example, MOL Changes supports teams with a sample documentation package covering method files, impurity tables and lot-level release records, which can be used to benchmark your own template before your next audit cycle.

This article is documentation guidance, not legal or regulatory advice. Consult qualified regulatory counsel before making compliance decisions. Reviewed by the MOL Changes technical documentation team. MOL Changes provides custom peptide synthesis and analytical services; this article is educational and does not constitute a product recommendation.